Biogen Announces European Commission Grants Marketing Authorization For QALSODY To Treat SOD1-ALS In Adults; Maintains Orphan Designation
Portfolio Pulse from Benzinga Newsdesk
Biogen has received marketing authorization from the European Commission for QALSODY, a treatment for SOD1-ALS, a rare and fatal genetic form of ALS. This is Biogen's third rare disease therapy approved in the EU, highlighting their commitment to addressing high unmet medical needs.
May 30, 2024 | 8:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biogen has received marketing authorization from the European Commission for QALSODY, a treatment for SOD1-ALS. This approval marks Biogen's third rare disease therapy in the EU, reinforcing its commitment to high unmet medical needs.
The approval of QALSODY by the European Commission is a significant milestone for Biogen, as it demonstrates the company's ongoing commitment to rare diseases and strengthens its portfolio in the EU. This positive regulatory news is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100